Correlation of tumor programmed death ligand-1 (PD-L1) expression and response to treatment with high-dose interleukin-2 (HD IL-2) in clear cell metastatic renal cell carcinoma (ccmRCC).
Hilda Crispin(University of Utah), Neeraj Agarwal(University of Utah), Alli Straubhar(University of Utah), Srinivas K. Tantravahi(University of Utah), David D. Stenehjem(University of Utah), Joseph A. Merriman(University of Iowa), Archana M. Agarwal(University of Utah), Austin Poole(University of Utah), Roberto Nussenzveig(University Pathologists), Mohamed E. Salama(The University of Texas at San Antonio Health Science Center)
Cited by 4
Related Papers
MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition
|Cancer Cell|2017|619
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors
|Journal of Clinical Oncology|2021|530
Spectrum of Epithelial Neoplasms in End-Stage Renal Disease
|The American Journal of Surgical Pathology|2006|484
A genetic mechanism for Tibetan high-altitude adaptation
|Nature Genetics|2014|441